liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
Altinbas Univ, Turkiye.
Med Univ Warsaw, Poland.
Med Univ Warsaw, Poland.
Jagiellonian Univ Med Coll, Poland.
Show others and affiliations
2023 (English)In: Clinical Kidney Journal, ISSN 2048-8505, E-ISSN 2048-8513, Vol. 16, no 12, p. 2378-2392Article, review/survey (Refereed) Published
Abstract [en]

There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood-brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects. Graphical Abstract

Place, publisher, year, edition, pages
OXFORD UNIV PRESS , 2023. Vol. 16, no 12, p. 2378-2392
Keywords [en]
adverse drug reaction; chronic kidney disease; cognitive impairment; drug prescription; medications
National Category
Urology and Nephrology
Identifiers
URN: urn:nbn:se:liu:diva-198864DOI: 10.1093/ckj/sfad239ISI: 001081414700001OAI: oai:DiVA.org:liu-198864DiVA, id: diva2:1808959
Note

Funding Agencies|The authors would like to thank Prof. Giovambattista Capasso, acting chair of Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT) Action and members of COST Action for their support.

Available from: 2023-11-01 Created: 2023-11-01 Last updated: 2024-05-03

Open Access in DiVA

fulltext(1080 kB)32 downloads
File information
File name FULLTEXT01.pdfFile size 1080 kBChecksum SHA-512
78cf6eb78ccfe110fb6f88ec50f3fba7154d3dc37d03b53a2a5bc5b87ecd749d85fad1154220b74b1b71371509bdb4edeb83ece6ef512941a62750337c5f5ec1
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records

Bruchfeld, Annette

Search in DiVA

By author/editor
Bruchfeld, Annette
By organisation
Division of Diagnostics and Specialist MedicineFaculty of Medicine and Health SciencesDepartment of Nephrology
In the same journal
Clinical Kidney Journal
Urology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar
Total: 32 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 59 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf